
With 20,000Pa Industrial-Grade Suction, This Eufy Robot Vacuum and Mop Hits a New Low on Amazon
That's where the eufy E25 Omni robot vacuum and mop combo is good at: With industrial-grade suction power, it ensures your floors are left immaculate after every clean. Few brands offer anything close to the 20,000Pa of suction that eufy delivers here, which makes it a rare find for those who want professional-level results at home.
For Prime Day, this model is available at an all-time low price, but you'll need to be a Prime member to claim the deal on Amazon: It has fallen to a mere $699, from its regular price of $1,199 and that's a staggering 42% discount on this model.
See at Amazon
What sets the eufy E25 Omni apart is its 20,000Pa Turbo Suction which competes with professional cleaning equipment. This level of suction enables it to pick up even the most embedded dirt and dander from carpets and hard floors. The HydroJet mopping system then fills in the vacuuming by scrubbing and cleaning your floors to leave them with a deep-down clean below the surface dust. The zero-tangle brush style is also a huge advantage for pet or long hair families as it does not permit hair to curl around the brush and needs less upkeep.
Edge-to-corner deep cleaning is another feature highlight of the E25 Omni: Its advanced sensors and mapping technology allow it to clean into corners and along edges where dirt accumulates. The obstacle avoidance feature keeps it from bumping into furniture and other objects with which it shares your house so that you needn't worry about it getting stuck or missing spots.
Among the most low-maintenance is the all-in-one station, auto-emptying and self-cleaning: When each cleaning cycle is complete, the robot returns to its charger, empties the dustbin and cleans itself which means you can do a tremendous amount of hands-off maintenance. This saves a massive amount of time and means you can go (up to 7) weeks without ever laying hands on the vacuum.
If you're looking for a robot vacuum that delivers industrial-grade cleaning, the eufy E25 Omni is the clear winner. With its current Prime Day price, there's never been a better time to upgrade your cleaning routine.
See at Amazon

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Microsoft Rushes To Plug SharePoint Flaws After Wave Of Cyber Intrusions
Reports suggest that Chinese?linked hackers exploited two unpatched flaws in on?premises SharePoint to breach around 100 organizations in a single weekend. Microsoft (MFT) rushed out fixes and urged everyone to update right away. On July 19, the Microsoft Security Response Center flagged a spoofing bug (CVE?2025?49706) and a remote code execution hole (CVE?2025?49704) in on?premises SharePoint. Warning! GuruFocus has detected 7 Warning Sign with MSFT. Advanced groups known as Linen Typhoon and Violet Typhoon have been chaining these vulnerabilities to slip into servers, and a less familiar actor called Storm?2603 is now using them too. Their favorite targets include government agencies, think tanks and universities across the U.S., Europe and East Asia. If your IT team hasn't applied the new SharePoint patches, any exposed server is at risk of having data from defense plans to donor lists stolen overnight. Microsoft pointed out that SharePoint Online in Microsoft 365 isn't affected, making the cloud version a safer bet when it comes to rapid security updates. Rolling out fixes is one thing; getting them installed in complex, custom environments is another. Until everyone catches up, expect more breach headlines. This incident is a stark reminder of why many organizations are accelerating moves from traditional on?premises software to cloud?hosted alternatives. This article first appeared on GuruFocus. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
12 minutes ago
- Yahoo
Corstasis Therapeutics Announces Appointment of Sanjeev Narula to its Strategic Advisory Board
HENDERSON, Nev., July 23, 2025--(BUSINESS WIRE)--Corstasis Therapeutics Inc. ( a late clinical-stage innovator of therapies that enhance options for the treatment of fluid overload in patients with cardiorenal and hepatic diseases, with the intent of lowering the overall cost of care, today announced that life science executive Sanjeev Narula has joined the company's Strategic Advisory Board. "Sanjeev's extensive strategic, financial and operational experience in large commercial-stage pharmaceutical companies make him a tremendous addition to our strategic advisory board," said Benjamin Esque, Chairman and Chief Executive Officer of Corstasis Therapeutics Inc. "We expect Corstasis will benefit greatly from Sanjeev's advice as we prepare our commercial strategy and pre-launch activities for Enbumyst™ ahead of its potential approval in September." Mr. Narula most recently served as the Chief Financial Officer of Intra-Cellular Therapies, Inc., which he joined in 2024. During his tenure, he played a crucial role in expanding the commercial and operational capabilities of the company , which culminated in the successful acquisition of Intra-Cellular Therapies by Johnson & Johnson for $14.6 billion less than a year later. Before Intra-Cellular, Mr. Narula served as the first Chief Financial Officer of Viatris, which he joined in 2020 when the company was formed through the combination of Mylan and Upjohn, a division of Pfizer Inc. Prior to Viatris, he served as Chief Financial Officer at Upjohn, overseeing finance, procurement and business technology for all functions of the business, and held several other financial leadership positions during his 16 years at Pfizer. "I am excited to join Corstasis as a strategic advisor at this critical inflection point in the company's journey, and look forward to contributing to its growth and capital strategy as it prepares for the potential launch of Enbumyst™," said Mr. Narula. About Corstasis Therapeutics Corstasis Therapeutics is a late clinical-stage biopharmaceutical company whose mission is to develop and commercialize enhanced outpatient treatment options for patients with cardiorenal and hepatic diseases, with the intent of improving outcomes and reducing overall healthcare costs. Our lead product, Enbumyst™ bumetanide nasal spray, has been developed for the short-term treatment of edema associated with congestive heart failure, liver and kidney disease, with an anticipated PDUFA action date of September 14, 2025. For more information, please visit View source version on Contacts Ben Esque, CEOCorstasis Therapeutics 702-541-9222Email: Info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
12 minutes ago
- Yahoo
Temenos CFO says US tariff 'wobbles' over for banks as shares soar after results
By Marleen Kaesebier (Reuters) -Banking software group Temenos' chief financial officer said on Wednesday "wobbles" over U.S. tariffs that caused deals to be delayed in the first quarter are over, as the company reported second-quarter results that beat analyst expectations. The news sparked a 22% surge in the group's shares at market open on Wednesday. By 0741 GMT shares were up 16.4% at 68.7 Swiss francs per share, on track for their best day in more than a year. "There are still tariff discussions, but I think banks, especially (those) printing very good results, have adapted this in their daily business," Takis Spiliopoulos told Reuters. After some worry and anxiety ahead of U.S. President Donald Trump's so-called "Liberation Day" tariff announcement on April 2, Temenos caught up on delayed deals quickly and has seen its banking customers going back to normal in the second quarter, Spiliopoulos said. On Tuesday after market close, Temenos reported adjusted earnings before interest and taxes of 111.6 million dollars in the quarter, above the 81.2 million dollars predicted by analysts in a company-provided poll. After what Baader Helvea analysts called "a perfect quarter for Temenos", the Swiss company also raised its full-year guidance, now expecting EBIT growth of at least 9% at constant currency from at least 5% before. "This beat and raise should help to boost investor confidence and trigger a rerating of the shares," Vontobel analyst Michael Foeth said. Spiliopoulos said the strong quarter, particularly across Europe and the Americas, "more than compensated" for a slow start to the year. While other Swiss businesses are also facing headwinds from a strong Swiss franc this quarter, Temenos, though headquartered in Geneva, Switzerland, reports in U.S. dollars. Spiliopoulos said he is therefore not worried about the impact of currency moves on the firm, which sees a very small portion of its revenues and costs denominated in Swiss francs. Temenos has profited from currency effects this quarter, he said. "We clearly have a benefit from reporting in dollars... so overall, we had a slight positive impact of about $1 million in the second quarter from FX," Spiliopoulos said.